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Moloney murine leukemia virus (M-MLV) repli-
cation is restricted in embryonic carcinoma (EC)
and embryonic stem (ES) cells, likely to protect
the germ line from insertionalmutagenesis. Pro-
viral DNAs are potently silenced at the level of
transcription in these cells. This silencing is
largely due to an unidentified trans-acting factor
that is thought to bind to the primer binding
site (PBS) of M-MLV and repress transcription
from the viral promoter. We have partially puri-
fied a large PBS-mediated silencing complex
and identified TRIM28 (Kap-1), a known tran-
scriptional silencer, as an integral component
of the complex. We show that RNAi-mediated
knockdown of TRIM28 in EC and ES cells
relieves the restrictionand that TRIM28 isbound
to the PBS in vivo when restriction takes place.
The identification of TRIM28 as a retroviral
silencer adds to the growing body of evidence
that many TRIM family proteins are involved in
retroviral restriction.
INTRODUCTION
Moloney murine leukemia virus (M-MLV) is a prototypical
simple retrovirus and replicates efficiently in most dividing
cells that express the virus receptor. Virus replication is re-
stricted, however, in mouse embryonic carcinoma (EC)
and embryonic stem (ES) cells (Barklis et al., 1986; Teich
et al., 1977). Although infection of EC or ES cells by
M-MLV results in the successful integration of the proviral
DNA into the genome, transcription from the viral
promoter in the long terminal repeat (LTR) is potently si-
lenced. This transcriptional silencing is attributed in part
to reduced transcription factor binding to the viral en-
hancers in the LTR (Hilberg et al., 1987; Linney et al.,
1984) and in larger part to the presence of repressive
trans-acting factors in these cell types (Akgun et al.,
1991; Flanagan et al., 1989; Tsukiyama et al., 1989).46 Cell 131, 46–57, October 5, 2007 ª2007 Elsevier Inc.A major target of this repression is the repressor binding
site (RBS), a DNA element of 17 bp contained within the
18 bp encoding the primer binding site (PBS) near the 50
end of theM-MLVRNA genome (Barklis et al., 1986; Feuer
et al., 1989; Loh et al., 1987). The PBS of the M-MLV ge-
nome is complementary to 18 nucleotides at the 30 end
of the host proline tRNA and is a critical sequence for virus
replication. The tRNApro is annealed to the PBS in the RNA
genome at the time of virus assembly and, upon infection,
is used as the primer for minus-strand DNA synthesis dur-
ing reverse transcription (Harada et al., 1979). The mech-
anism of RBS-mediated transcriptional repression is un-
known but is thought to act as a DNA element in the
context of the integrated provirus. Therefore, RBS func-
tion is thought to be distinct from the role of the PBS in
tRNA annealing and priming on the viral RNA. Evidence
has been obtained that the RBS is able to repress
LTR-driven transcription in an orientation- and position-in-
dependent fashion and can function even when placed
outside of the transcriptional unit (Loh et al., 1990;
Petersen et al., 1991). Subsequent to this immediate tran-
scriptional repression, the provirus is frequently further
silenced by DNA methylation (Niwa et al., 1983). In EC
cells the RBS sequence can repress nearby heterologous
promoters such as the SV40 early and adenovirus major
late promoters, and such repression is not blocked by
a variety of known DNA insulator sequences (Modin
et al., 2000b). The repression mediated by the RBS can
be relieved by a single G to A base pair mutation, known
as the B2 mutation, within the DNA sequence encoding
the PBS (Barklis et al., 1986). The repression can also be
relieved by replacing the PBS of M-MLV with a sequence
complementary to another cellular tRNA such as gluta-
mine (Gln) tRNA (Grez et al., 1990; Petersen et al., 1991).
There is strong evidence that the RBS mediates its re-
pressive activity through a trans-activating DNA-binding
factor. The repressive activity of the RBS is saturable by
transfection of increasing amounts of DNA containing
the RBS sequence (Loh et al., 1988). The presence of
a binding factor has also been detected in EC cell nuclear
extracts using a probe spanning the PBS sequence of M-
MLV by exonuclease III protection assays (Loh et al.,
1990). This exonuclease III protection footprint is reduced
upon either differentiation of the EC cells or the use of
a probe containing the B2 mutation, strongly suggesting
that the presence of this factor correlates with repression.
Similar experiments performed by electrophoretic mobil-
ity shift assay (EMSA) using M-MLV PBS sequences as
a probe have shown that DNA-binding activity was en-
riched in nuclear extracts from EC cells when compared
with differentiated cell lines (Petersen et al., 1991).
RBS-mediated repression of M-MLV is not limited
to mouse ES and EC lines but has been observed in early
mouse embryos as well as primary stromal cells from
mouse bone marrow (Haas et al., 2003; Vernet and Ce-
brian, 1996). Most intriguingly, it has also been observed
to occur in a human hematopoietic cell line and primary
human hematopoietic cells isolated from umbilical cord
blood (Haas et al., 2003). This raises the possibility that
viruses such as human T-lymphotropic virus type 1
(HTLV-1) that also use a tRNApro PBS sequence might
be targeted for repression in pluripotent cells. Other PBS
sequences have also been shown to be specifically re-
pressed in EC cells, such as the PBS for lysine-1,2 tRNA
found in Mason-Pfizer monkey virus, visna virus, and
spumavirus. This raises the possibility that specific cellular
repressors may also target these viruses for silencing
(Modin et al., 2000a; Yamauchi et al., 1995). There is a ra-
tionale for the evolution of repression at PBS elements:
during reverse transcription, the PBS sequence on one
strand of the viral DNA is actually synthesized by reverse
transcription of the cellular tRNA itself. Thus, the viral
PBS sequence is a uniquely effective target site for repres-
sion by the host since any escape point mutations in the
PBS sequence would quickly revert to the original se-
quence during viral replication.
Previous attempts to purify the RBS binding factor by
biochemical means have been unsuccessful due to the
factor’s apparent instability. However, it appeared that
such purification might be possible if biochemical condi-
tions were found under which the factor was stable (Ya-
mauchi et al., 1995). We undertook a search for such con-
ditions, partially purified the factor, successfully identified
a cellular component of the complex, and demonstrated
its requirement for RBS-mediated silencing.
RESULTS
Purification of the RBS Complex
To characterize the RBS binding factor, nuclear extracts
were prepared from the repressing F9 EC cell line and
differentiated control lines, and RBS binding activity was
detected by electrophoresis mobility shift assays (EMSA)
using a 28 bp 32P-labeled probe containing the M-MLV
PBS. This probe has been previously been used to detect
RBS binding activity in F9 and other EC cell lines, and the
resulting shift was shown to be sensitive to the B2 muta-
tion and to competition by cold probe (Petersen et al.,
1991; Yamauchi et al., 1995). Extracts of F9 cells con-
tained significant binding activity, producing a single
shifted band of very lowmobility (Figure 1A). NIH/3T3 cellsyielded very low levels of binding activity, and HeLa,
RAT2, and 293A cells showed no detectable activity.
The F9 nuclear extracts were fractionated by a variety of
procedures, and the fate of the RBS binding activity was
monitored by EMSA. When the crude lysates were treated
with increasing concentrations of ammonium sulfate, the
majority of the RBS binding activity was recovered in the
precipitate from the 40% ammonium sulfate fraction
(Figure 1B). To purify the activity further, the precipitate
was dissolved in 1 M ammonium sulfate and applied to
a butyl sepharose hydrophobic interaction column, and
the bound proteins were eluted with a decreasing salt
concentration gradient. The bulk of the activity eluted in
a relatively broad peak centered at 0.7–0.4 M ammonium
sulfate (Figure 1C). Proteins in fractions 13–40 from this
column were then concentrated and applied to a Se-
phacryl S-500 gel filtration column (Figure 1D). The activity
eluted from this column in a single relatively tight peak,
with the majority found in fractions 17–21 (Figure 1D).
The behavior in this gel filtration step suggested that the
RBS binding factor was large. Superose 6 gel filtration
was performed to obtain a better estimate of the size of
the complex. The RBS binding factor eluted from these
columns in a broad peak, indicative of an apparent size
ranging from about 2 to 0.7MDa, and centered on approx-
imately 1.3 MDa (see Figure S1A in the Supplemental Data
available with this article online). The large size suggests
that the activity probably resides in a multisubunit com-
plex. These various chromatographic steps were assem-
bled into a final purification scheme used routinely for
preparation of the activity (Figure 1E).
Identification of TRIM28 as a Possible
Component of RBS Complex
To identify possible components of the complex, the most
highly purified fractions were probed by EMSA with the 28
bp M-MLV PBS DNA, and the shifted band defining the
complex was excised from the gel. The proteins associ-
ated with the DNA were analyzed by mass spectroscopy
(Table 1). Themajor proteins identified were tripartite motif
protein 28 (TRIM28, Kap-1, Tif1-beta) and valosin con-
taining protein (VCP, p97). VCP is an extremely abundant
protein accounting for 1% of the total cellular protein, is
predominantly localized to the cytoplasm, and is involved
in a variety cellular processes including endoplasmic retic-
ulum (ER)-associated degradation, apoptosis, and mem-
brane fusion (Wang et al., 2004). Due to its cytoplasmic lo-
calization, VCP was unlikely to be biologically relevant to
RBS-mediated repression and, because of its high abun-
dance in the cell, was assumed to be a contaminant. The
TRIM28 protein, 89 KDa in size, is a member of the tripar-
tite motif (TRIM) family and contains three characteristic
RING finger, B box, and coiled-coil motifs at its N termi-
nus. TRIM28 functions as corepressor with the Kru¨ppel-
associated box (KRAB) zinc finger DNA-binding proteins
(Friedman et al., 1996) and acts by bridging the KRAB do-
main of the finger proteins to several known transcriptional
corepressors, including the NuRD histone deacetylaseCell 131, 46–57, October 5, 2007 ª2007 Elsevier Inc. 47
Figure 1. Biochemical Purification of the RBS Binding Complex from F9 Nuclear Extracts
(A) Upper panel: nuclear extracts from F9, HeLa, NIH 3T3, RAT2, and 293A were prepared and used in EMSA with a 33P-labeled 28 bp probe cor-
responding to the WT M-MLV RBS sequence. Lower panels: western blots of the same nuclear extracts probed with anti-TRIM28 (ab22553) and
anti-actin antibodies.
(B) Upper panel: EMSA performed as above, on 25%, 40%, and 100% ammonium sulfate fractions of F9 nuclear extracts. Lower panel: anti-TRIM28
western blot of same fractions.
(C) EMSA performed as above on fractions from butyl sepharose FF fractionation of 40% ammonium sulfate cut from (B). Lower panel: anti-TRIM28
western blot of same fractions.
(D) EMSA performed as above on Sephacryl S-500 fractions from fractionation of 13–40 from (C). Lower panel: anti-TRIM28 western blot performed
on same fractions.
(E) Graphical representation of final purification scheme used.complex, the histone H3 K9 methyltransferase ESET, and
HP1 (Le Douarin et al., 1996; Schultz et al., 2001, 2002).
Remarkably, the transcriptional repression induced by
TRIM28 is heritable over many cell cycles, even after the48 Cell 131, 46–57, October 5, 2007 ª2007 Elsevier Inc.KRABboxDNA-binding protein targeting TRIM28 to a pro-
moter is no longer present, suggesting that TRIM28 is in-
volved in the recruitment of proteins required for heritable
gene silencing (Ayyanathan et al., 2003). TRIM28 is also
required for the differentiation of EC cells, as F9 EC cells
expressing a TRIM28 mutant defective for association
with HP1 are not able to differentiate correctly (Cammas
et al., 2004). TRIM28 is therefore an attractive candidate
as a component of the RBS silencer complex.
To confirm that TRIM28 was a plausible member of the
RBS complex, western blots were performed on the frac-
tions collected during its biochemical purification to deter-
mine whether the presence of TRIM28 tracked with the
presence of the RBS binding activity. In the ammonium
sulfate precipitation, levels of TRIM28 correlated well with
levels of binding activity, and both the majority of the RBS
binding factor and the TRIM28 was recovered in the 40%
fraction (Figure 1B). In the hydrophobic interaction column,
the levels of TRIM28 and RBS binding activity correlated
well, with both enriched in fractions 13–40 (Figure 1C).
Finally, in the gel filtration column, the abundance of
TRIM28 tracks nearly perfectly with the RBS binding
activity, with fractions 17–21 having the majority of both
TRIM28 and binding activity (Figure 1D). These results are
consistent with TRIM28 being present in the complex.
TRIM28 Is an Integral Part of the RBS Binding
Complex
To determine whether TRIM28 is a true component of the
RBS binding complex, a series of EMSA reactions were
performed using F9 nuclear extracts and the 28 bp PBS
sequence as probe. To these binding reactions, an anti-
TRIM28 or anti-FLAG control antibody was added in an at-
tempt to supershift the RBS complex to a lower mobility
species. In the presence of increasing TRIM28 antibody
and not the control antibody, the complex was indeed
supershifted (Figure 2A, lanes 5–7). Furthermore, compe-
tition with an excess of either WT or B2 mutated cold DNA
showed that this supershift was specifically competed by
the WT PBS sequence (Figure 2A, lanes 14–15). The
supershift experiments demonstrate that TRIM28 is an
integral component of the RBS complex. To extend this
observation to other cell lines, supershifts were also per-
formed using nuclear extracts from PCC4 cells, another
Table 1. List of Gene Products Identified by lc-ms-ms
Mass Spectroscopy
Protein Identified No. Peptides Matched
Tripartite motif protein
28 (TRIM28)
8
Valosin-containing
protein (VCP/p97)
9
Albumin 1
Ribosomal protein L14 1
List of gene products identified from lc-ms-ms mass spec-
troscopy of excised EMSA band using 28 bp RBS sequence
as probe. The number of different peptides of each protein
identified is shown in right column. Proteins are listed in order
of statistical probability of correct match.EC line previously shown to possess RBS activity (Pe-
tersen et al., 1991), and from the ES cell line JM1. In
both cases, the RBS complex was observed to be super-
shifted by an anti-TRIM28 antibody and thus contains
TRIM28 (Figure S2).
To test whether TRIM28 was stably associated with the
components of the RBS complex, the F9 nuclear extracts
were immunodepleted by addition of anti-TRIM28 anti-
bodies followed by removal of the antibody on protein
A/G sepharose beads. Tests of the resulting depleted
extracts showed that immunodepletion with polyclonal
TRIM28-specific antisera, but not with control antisera,
led to complete removal of RBS binding activity from F9
nuclear extracts (Figure 2B). To further test if the intact
RBS complex was indeed bound to the TRIM28-specific
antibodies, we asked whether RBS binding activity could
be recovered from the protein A/G sepharose beads used
in a successful TRIM28 immunodepletion. Such sephar-
ose beads were added directly to an EMSA binding reac-
tion and low levels of RBS binding activity were indeed
detectable (Figure 2C). Presumably, TRIM28 and the
complete RBS binding complex was able to dissociate
from the TRIM28 antibody and bind to the DNA probe.
This suggests that at least a portion of the TRIM28 remains
stably associated with all the components of the RBS
binding complex.
Differentiation of F9 Cells Leads to a Decrease
of TRIM28 Levels and a Concomitant Loss
of RBS Activity
Differentiated cell lines do not restrict M-MLV in an RBS-
dependent manner (Petersen et al., 1991). In addition, dif-
ferentiation of EC cells by retinoic acid (RA) followed by
treatment with the DNA demethylating agent 5-azacyti-
dine (azaC) leads to reactivation of silenced M-MLV provi-
ruses, whereas azaC treatment alone does not (Niwa
et al., 1983). These results suggest that differentiation of
F9 cells should lead to loss of RBS binding activity. To
test this notion, F9 cells were treated with RA at 1 mMcon-
centration for either 2, 4, or 7 days. Nuclear extracts were
prepared from these cells (as well as from time matched
control cells), and these extracts were used in EMSA reac-
tions with the 28 bp MuLV PBS probe. As RA-induced dif-
ferentiation progressed, RBS binding activity decreased
and, after 7 days, was completely absent (Figure 3A). It
has been previously been shown that differentiation of
F9 cells into primitive endoderm-like cells with RA can
lead to a decrease in steady-state TRIM28 levels (Cam-
mas et al., 2004). To test for this decrease in TRIM28 in dif-
ferentiated F9 cells and to test whether the decrease of
TRIM28 levels correlated with the disappearance of RBS
binding activity, the same nuclear extracts were analyzed
for TRIM28 levels by western blot (Figure 3A). As
expected, the steady state levels of TRIM28 decreased
during differentiation and, after 7 days, were almost com-
pletely absent. These results suggest that the loss of
TRIM28 may be responsible for the loss of RBS activity
in these cells.Cell 131, 46–57, October 5, 2007 ª2007 Elsevier Inc. 49
Figure 2. TRIM28 Is an Integral Component of the RBS Binding Complex
(A) EMSA performed with 33P-labeled 28 bp probe corresponding to WT M-MLV RBS sequence on F9 nuclear extracts. Increasing amounts of anti-
TRIM28 (lanes 5–7) or anti-FLAG (lanes 2–4) antibodies were included (1, 5, and 10 mg of antibodies as indicated; lanes 2 and 5, 3 and 6, and 4 and 7,
respectively). Competitions with cold DNA were performed with 0.5, 1, and 2 mg of cold WT probe (WT; lanes 11, 12, and 13) or probe DNA containing
B2 mutation (B2; lanes 8, 9, and 10) as indicated. Competitions with 2 mg of cold probe, either WT (lane 14) or B2 (lane 15) were also performed in
presence of 5 mg of anti-TRIM28 antibody.
(B) Upper panel: F9 nuclear extract was immunodepleted with 3 mg TRIM28 polyclonal antibody, 3 mg TRIM28monoclonal antibody (which is unable to
immunoprecipitate TRIM28), or 3 mg anti-c-myc antibody. Extracts were used in EMSA reactions as above. Lower panel: LHS shows anti-TRIM28
western blot of depleted extracts used in upper panel. RHS shows anti-TRIM28 western blot of boiled protein A/G beads used in immunodepletions.
(C) EMSA performed as above on protein A/G beads from immunodepletion as in (B).During the course of RA-induced differentiation, it was
observed that the RBS shifted band subtly changed its
mobility. This mobility change was also observed in the
superose 6 fractionation of the RBS complex (Fig-
ure S1A). To determine if this change in mobility was due
to a loss of TRIM28, supershifts with TRIM28 antibodies
were performed on the extracts from cells treated with RA
for 2 and 4 days, as well as a selection of fractions from the
superose6 experiment (Figure3B; FigureS1B). In all cases,
the RBS complex was supershifted by the TRIM28 anti-
body suggesting that TRIM28 is not lost from these
complexes.
Knockdown of TRIM28 in ES and EC Cells Results
in a Loss of RBS Binding Activity in These Cells
The correlation of TRIM28 levels with RBS binding activ-
ity during differentiation suggested that TRIM28 might50 Cell 131, 46–57, October 5, 2007 ª2007 Elsevier Inc.be essential for RBS function. To test this notion, we
asked whether RNAi-mediated knockdown of TRIM28
in EC and ES cells would lead to a loss of RBS binding
activity. We used a retroviral RNAi system to target en-
dogenous TRIM28 for stable knockdown in F9 and PCC4
EC lines, as well as the ES cell line JM1. Various primers
targeted to the coding sequence of the mouse TRIM28
gene were used and pools of cells stably expressing
various different RNAi constructs were analyzed for
both expression of TRIM28 as well as RBS binding ac-
tivity by EMSA (Figures 4A and 4B; Figure S3). In F9
cells, nearly complete knockdown of TRIM28 in Pool 6
lead to abrogation of RBS shift activity. Additionally, par-
tial knockdown of TRIM28 correlated with a significant
decrease in RBS binding activity (Pools 2 and 3). Com-
plete knockdown of TRIM28, however, was found to be
extremely detrimental to F9 cells, leading to growth
Figure 3. Differentiation of F9 Cells
Leads to a Decrease of TRIM28 Levels
and a Concomitant Loss of RBS Activity
(A) Upper panel: EMSA performed with nuclear
extracts from F9 cells treated with 1 mM reti-
noic acid for 2, 4, or 7 days, or from time
matched untreated controls, and with 33P-la-
beled WT DNA probe. Lower panels show
western blots of same extracts using anti-
TRIM28 antibody and anti-actin antibody.
(B) EMSA performed with extracts from F9
cells treated with RA as above, but every
second lane was preincubated with 5 mg anti-
TRIM28 antibody.arrest after a short number of cell cycles and a flattened
morphology characteristic of cell-cycle arrest (data not
shown). Surviving stable clones from Pool 6 were con-
sistently shown to express higher levels of TRIM28, sug-
gesting that complete knockdown of TRIM28 was se-
lected against in cell lines which could form colonies.
Therefore, to obtain populations with reduced levels of
TRIM28, clonal cell lines from Pool 2 with partial knock-
down were generated, along with clones expressing a
scrambled siRNA control. One such line, Clone 2.3 (2.3),
showed a robust knockdown of TRIM28 and no obvious
grossmorphological phenotype. As observed in the pools,
the partial TRIM28 knockdown in this line correlated well
with a decrease in RBS binding activity (Figure 4A). A
possible mechanism for the decrease in RBS-mediated
silencing in Clone 2.3 is that the knockdown of TRIM28 is
causing these F9 cells to differentiate, as TRIM28 has
a documented role in the differentiation of F9 cells
(Cammas et al., 2004). To address this possibility, F9,
Scram2, and Clone 2.3 cells were tested for two markers
of their differentiation status.OCT3/4 is awell documented
marker of pluripotency that has been shown to decrease
upon F9 cell differentiation (Lenardo et al., 1989), and
endo-A cytokeratin (TROMA-1) is known to only be ex-
pressed in F9 cells that are differentiated (Oshima, 1982).
Both OCT3/4 and Endo-A cytokeratin showed little differ-
ence in levels among thesecell lines, especiallywhencom-
pared to the dramatic change in their levels in the samecell
lines after differentiation by treatment with RA (Figure S4).
These results suggest that TRIM28 knockdown in Clone
2.3 did not induce a normal program of differentiation,nor did it affect the ability of the cells to differentiate cor-
rectly with RA.
Knockdown of TRIM28 was also attempted in an ES cell
line to test for its effects on RBS activity. In JM1 ES cells,
TRIM28 knockdown was even more detrimental to viabil-
ity than in F9 cells. Partial knockdown of TRIM28 did cor-
relate with decreased RBS activity (Figure S3), but pools
of cells expressing the most efficient RNAi construct
(Pool 6) were observed to have an extremely high rate of
cell death (data not shown), and these ES lines were not
used for further study.
Knockdown of TRIM28 in PCC4 cells, another EC line,
was considerably more successful: all siRNA constructs
led to a large decrease in TRIM28 levels and a near com-
plete loss of RBS activity (Figure 4B). As in F9 cells, Pool 6
had the most efficient knockdown; however, in contrast to
F9 cells, this pool was viable and showed no gross mor-
phological differences from the control PCC4 cells. To en-
sure that the knockdown construct was not acting through
an off-target gene, a myc/HIS-tagged TRIM28 construct
designed to be resistant to siRNA knockdown was tran-
siently reintroduced into Pool 6 by adenovirus transduc-
tion. This reexpression of TRIM28 resulted in recapitula-
tion of RBS activity in this cell line (Figure 4B), whereas
transduction with an empty adenoviral control vector did
not. To further ensure that the reconstitution of RBS activ-
ity in this cell line was due to the exogenous expression of
TRIM28-myc/HIS, a supershift was performed in these
extracts using a c-myc antibody (Figure 4B). The c-myc
antibody indeed supershifted the restored complex,
confirming that the exogenously expressed TRIM28 hadCell 131, 46–57, October 5, 2007 ª2007 Elsevier Inc. 51
recapitulated a functional RBS complex. These results
show that TRIM28 is required for RBS binding activity
and that knockdown of TRIM28 can eliminate the RBS
complex without inducing differentiation.
Knockdown of TRIM28 in F9 and PCC4Cells Leads
to an Attenuation of PBS-Mediated Silencing
of M-MLV In Vivo
The observation that TRIM28 levels correlated with RBS
binding activity suggested that knockdown of TRIM28
Figure 4. RNAi-Mediated Knockdown of TRIM28 Correlates
with Loss of RBS Activity in F9 and PCC4 Cells
(A) Upper panel left, EMSA performed using 33P labeled 28 bp probe
corresponding to WT M-MLV RBS sequence and nuclear extracts
prepared from F9 cells previously transduced with pSUPERRETRO-
RNAi-puro construct and placed under puromycin selection. Each pool
received a different siRNA sequence targeted to a different CDS se-
quence of TRIM28. Nuclear extract levels were equalized by Bradford
protein assay. Upper panel right, same as above except nuclear
extracts were prepared from clonal Scram2 and 2.3 cell lines. (2.3 is
a clonal cell line derived from Pool 2) Lower panels: anti-TRIM28 and
anti-HDAC-1 western blots performed on same extracts as in upper
panel. HDAC-1 is used as a loading control. EV, empty vector.
(B) Upper panel EMSA performed (as above) with nuclear extracts from
PCC4 cells targeted for TRIM28 RNAi knockdown using same con-
structs as above and also complementation of RBS activity by exoge-
nously expressed TRIM28 in cell line Pool 6 using an adenoviral ex-
pression system. +AdTRIM denotes infection of cell line 24 hr prior
to preparation of nuclear extract with an adenovirus expressing
TRIM28 with a C-terminal myc/HIS tag. (MOI 100) +Ad denotes infec-
tion of cell line 24 hr prior to preparation of nuclear extractwith a control
adenovirus that does not express TRIM28 (MOI 100) Final two lanes
show PCC4 WT nuclear extract and TRIM28-myc/HIS complemented
Pool 6 nuclear extract incubated with 3 mg of anti-c-myc antibody,
which supershifts RBS complex in TRIM28-myc/HIS expressing cells.
Lower panels: anti-TRIM28, anti-c-myc, and anti-actin western blots
performed on same extracts as in upper panel.52 Cell 131, 46–57, October 5, 2007 ª2007 Elsevier Inc.should relieve repression of M-MLV transcription. To
analyze the effect of TRIM28 knockdown on PBS-medi-
ated repression in F9 and PCC4 cells, two M-MLV-based
retroviral vectors, LJ-PAdMLPEnh (WT) and LJB2-
ADMLPEnh (B2), were used. These vectors both express
the neomycin resistancemarker from the adenoviral major
late promoter, and are identical except that the former has
a wild-type proline PBS and the latter a B2 mutated PBS
(Modin et al., 2000b). M-MLV particles pseudotyped
by the VSV G protein and containing either the LJ-
PAdMLPEnh or the LJB2-ADMLPEnh vectors were
produced, and the infectivity of each of these virus prepa-
rations was determined by colony formation assays in me-
dium containing G418. The WT vector is repressed by
RBS binding activity and the B2 vector is not, and there-
fore, the ratio of the titers of these viruses in a particular
cell line is a measure of the RBS activity in that cell line.
Rat2 cells lack RBS-mediated repression activity, and
therefore, the WT and B2 viruses infect these cells with
very similar efficiencies. To correct for variations in titers
between virus preparations, we chose to use this cell line
as the standard, and the ratios of the titers of the B2/WT
viruses were all normalized to the ratio of titers in this cell
line. In F9 and PCC4 cells, the titer of the WT virus was
repressed 40- and 70-fold, respectively, over that of the
B2 virus, demonstrating that these cells possess a strong
RBS-silencing activity (Figure 5). In the F9 Scram2 cell
line and PCC4 Scramble pool cells, which both express
a control scrambled siRNA hairpin, an even greater level
of repression was observed; the titer of the WT virus was
repressed nearly 60-fold in F9 cells and over 200-fold in
PCC4 cells when compared to the B2 virus (Figure 5).
This increase in repression over the parental line was con-
sistently observed in cell lines stably expressing control
siRNA hairpins and may be due to nonspecific effects of
these siRNA hairpins on the cell, such as activation of the
interferon response (Bridge et al., 2003). In Clone 2.3 cells,
where TRIM28 levels were modestly reduced by RNAi, a
decrease in the fold repression from the parental cell line
of 8.5-fold was observed (Figure 5). In PCC4 Pool 6 cells,
where a better knockdown was observed, there was a
more dramatic effect, with a decrease in the fold repres-
sion from the parental cell line of nearly 12-fold (Figure 5).
(The results for the individual experiments are shown in
Figure S5). We note that despite the high efficacy of the
RNAi knockdown of TRIM28 in PCC4 Pool 6, the ratio of
the titers of the WT virus compared to the B2 virus does
not return to 1 as in RAT2 cells, This could be due to the
very low level of TRIM28 that is still present in these cells
(data not shown) Taken together, these results confirm
that knockdown of TRIM28 causes a significant decrease
in RBS-dependent silencing of M-MLV and strongly sug-
gests that TRIM28 is required for this process.
TRIM28 Is Present at the PBS In Vivo and Its
Presence Is Correlated with Viral Silencing
If TRIM28 is indeed critical for RBS binding and activity,
it should be bound to the RBS in vivo when an integrated
Figure 5. RNAi-Mediated Knockdown of
TRIM28 Relieves PBS-Mediated Repres-
sion of M-MLV
RAT2, F9, Scram2, 2.3, PCC4, PCC4
SCRAMBLE pool and PCC4 Pool 6 cell lines,
were infected with VSV-G pseudotyped M-
MLV containing either LJ-PAdMLPEnh (WT)
or LJB2-ADMLPEnh (B2) constructs. Infec-
tion efficiency in each cell line was monitored
by colony count after 2 weeks of G418 selec-
tion. Graph shows ratio of B2/WT infection
efficiency in each cell line, normalized with
RAT2 = 1. Error bars show ± standard error,
with n = 3 (F9 data) and n = 2 (PCC4 data).M-MLV provirus is silenced and absent when it is not.
Transcriptional corepressors that interact with TRIM28
and mediate its activity could also be bound at the RBS
in repressing cells. To investigate these predictions, chro-
matin immunoprecipitation (ChIP) experiments were per-
formed on two previously characterized F9 cell lines that
contain a single copy of an M-MLV-based vector inte-
grated into the same genomic locus (Berwin and Barklis,
1993). One cell line (R6A4) has a wild-type PBS and the
other (R6C2) has a PBS carrying the B2 mutation
(Figure 6A). The R6A4 line does not express the b-galacto-
sidase reporter gene from the viral genome since the LTR
is silenced by the wild-type PBS and also has been further
silenced by subsequent DNA methylation (Berwin and
Barklis, 1993); the R6C2 line does express b-galactosi-
dase, as the vector contains the B2 mutation (Figure 6A).
Chromatin immunoprecipitations were performed on
both R6C2 and R6A4 cell lines using antibodies specific
for TRIM28 and a histone H3 dimethyl Lysine 9 (diMeH3
K9) antibody. The diMeH3 K9 antibody was selected as
the histone H3 K9methyltransferase ESET is known to as-
sociate with TRIM28, and histone H3 lysine 9 methylation
has been shown to correlate with loci silenced by TRIM28
(Schultz et al., 2002). The ChIP assay showed that both
TRIM28 and diMeH3K9 are highly enriched at the PBS in
the R6A4 as compared to the R6C2 cell line (Figure 6B).
At the same time, the levels of binding to the housekeep-
ing GAPDH gene were tested, and no difference between
the cell lines was observed (Figure 6B). Thus, the in-
creased binding of TRIM28 and the increased presence
of histone H3 lysine 9 methylation at the proviral loci
with the wild-type PBS over the B2 PBS are site specific.
These results provide evidence that TRIM28 is indeed
selectively bound at the wild-type PBS of an integrated
M-MLV genome and that the B2 mutation decreases
that enrichment of TRIM28 at this site, thereby attenuating
its repressive influence. In order to confirm this observa-tion, this ChIP assay was also performed with an alterna-
tive TRIM28 antibody as well as antibodies to the TRIM28
interaction partners HP1a, HP1g ESET, and HDAC1.
These results confirm that TRIM28 is enriched at the WT
PBS in the R6A4 cell line and suggest that HP1g is also
specifically recruited to a site of PBS-mediated repression
by TRIM28 (Figure S6). These results are consistent with
observations suggesting that the ability of TRIM28 to re-
press transcription is linked to its binding to HP1 (Sripathy
et al., 2006).
DISCUSSION
It has been known for over 30 years that murine leukemia
proviruses are silenced in ES and EC cells (Teich et al.,
1977). This restriction of proviruses in pluripotent cells is
likely to have evolved to protect the embryo from the reac-
tivation of endogenous retroviruses and retrotransposons
that could cause damaging mutations in the germ line and
early progenitor cells. These elements might well other-
wise be expressed after the genome-wide DNA demethy-
lation that occurs at several stages during the develop-
ment of the mammalian embryo (Morgan et al., 2005).
Early studies suggested that this silencing was mediated
by the binding of a factor to the PBS to repress transcrip-
tion from the integrated provirus (Barklis et al., 1986). The
identity of the cellular factors involved in this process,
however, has remained unknown. In this paper, we pro-
vided evidence that the cellular factor TRIM28 is a integral
component of the RBS binding complex found in EC and
ES cells (Figures 1 and 2; Figure S2). TRIM28 is a known
transcriptional corepressor, acting as a bridge between
KRAB-domain zinc finger DNA binding factors and other
transcriptional repressors such as the NuRD deacetylase
complex, the histone H3 K9 methyltransferase ESET, and
HP1 (Le Douarin et al., 1996; Schultz et al., 2001, 2002).Cell 131, 46–57, October 5, 2007 ª2007 Elsevier Inc. 53
Figure 6. TRIM28 Is Present at the PBS
of M-MLV In Vivo when Silencing Takes
Place
(A) Cartoon depicting proviral constructs stably
integrated in the same genomic location in cell
lines R6A4 and R6C2. Cell line R6A4 has a WT
PBS sequence that leads to silencing of the ad-
jacent LTR, and R6C2 has a B2 mutated PBS,
and therefore, the adjacent LTR remains unsi-
lenced.
(B) Chromatin immunoprecipitations using
anti-TRIM28, anti-histone H3 di-methyl K9
(H3 K9 Di Me), and anti-c-Myc antibody as
a control. Upper panel shows PCRs performed
using primers specific to PBS region of M-
MLV; lower panel shows control primers di-
rected to endogenous GAPDH gene. One-hun-
dred percent control is arbitrarily defined as
signal of 10% Input PCR of ChIP. Dilutions of
all PCR products were performed to confirm
that PCR was in linear range of amplification
(data not shown).Through these interactions, TRIM28 is recruited to cellular
promoters and induces heritable gene silencing.
We found that knockdown of TRIM28 results in a spe-
cific alleviation of the repression in F9 and PCC4 cells (Fig-
ure 5) and that TRIM28 is present at the PBS of integrated
M-MLV proviruses when repression takes place (Figure 6;
Figure S6). This suggests that TRIM28 has an essential
role in orchestrating the PBS-mediated silencing of inte-
grated M-MLV proviruses in EC and ES cells, much as it
does in silencing other target genes. While TRIM28 is
apparently required for silencing, we note that it is not
sufficient. Many differentiated cell lines that do not silence
M-MLV still express high levels of TRIM28 (Figure 1A), and
so other factors must regulate its function or otherwise be
limiting determinants of its silencing activity.
TRIM28mayplayan important role inearly development,
especially in ESandother pluripotent cells. Duringdifferen-
tiation of EC cells, the intracellular distribution of
TRIM28 protein changes from a diffuse nuclear staining to
discrete foci colocalizing with heterochromatin, and its
steady-state levels decrease considerably (Cammas et al.,
2004; Figure 3). In early embryonic cells, TRIM28 has
been shown to reside in complexes with a variety of early
pluripotent markers including Nanog and Dax-1 (Wang
et al., 2006). Interactions with these same factors may
well be important in regulating TRIM28-mediated silenc-
ing of proviruses in these cells. Retroviral repression
through the RBS element, however, may also involve spe-
cific and proprietary cofactors.
As no DNA-binding activity has been demonstrated for
TRIM28 and as recombinant GST-TRIM28 appears to be54 Cell 131, 46–57, October 5, 2007 ª2007 Elsevier Inc.unable to recapitulate a mobility shift of the wild-type
PBS sequence (data not shown), we expect that the
RBS binding complex contains at least one additional fac-
tor besides TRIM28. A logical candidate for such a factor
would be one of the KRAB-box containing zinc finger pro-
teins found expressed in both ES and EC cells. There are
approximately 290 found in themammalian genome (Urru-
tia, 2003), and such a protein would have the requisite
ability to bind the RBS sequence and concomitantly re-
cruit TRIM28 to induce silencing. In addition, these zinc
finger proteins are among the few that are capable of rec-
ognizing an asymmetric DNA sequence as long as 17 bp,
the size of the critical RBS element. We have been unable
to identify such a factor in our purified preparations to date
despite numerous attempts. This may be because the fac-
tor is present at very low abundance; it is thought that the
KRAB domain can bind a trimer or possibly a hexamer of
TRIM28, and if so, the zinc finger protein would be stoi-
chiometrically underrepresented in the complex (Peng
et al., 2000). We note that many KRAB box zinc finger pro-
teins are able to dimerize (Urrutia, 2003) and that if each
KRAB box were to bind a hexamer of TRIM28, the com-
plex would be approximately the size of the RBS binding
activity as judged by size exclusion chromatography.
A growing body of evidence suggests that many mem-
bers of the TRIM family of proteins constitute an antiviral
(especially antiretroviral) defense mechanism for the cell
(Nisole et al., 2005). TRIM proteins have been shown to re-
strict multiple stages of the viral life cycle. TRIM5a has
been shown to be responsible for HIV-1 and N-tropic M-
MLV restriction in Old World monkeys and many other
mammals. TRIM5a restriction appears to take place in the
cytoplasm and predominantly occurs before reverse tran-
scription (Nisole et al., 2005). TRIM22 and TRIM32 have
also been implicated in the restriction of HIV-1 (Nisole
et al., 2005). These proteins appear to target HIV-1 tran-
scription from the LTR by either binding to the Tat transac-
tivator or through an unspecified mechanism. TRIM19
(better known as PML) has also been implicated in the re-
striction of several RNA viruses including vesicular stoma-
titis virus (VSV), influenza A, HIV-1, and human foamy virus
(HFV) (Nisole et al., 2005). The finding that TRIM28 has
a specific role in inhibiting M-MLV in pluripotent cells
strengthens the argument that the TRIM protein family
possibly evolved to protect cells from viral infection. It
should also be noted the PBS-mediated silencing of retro-
viruses may be common to many mammals; human he-
matopoietic cells are also able to restrict M-MLV in a
PBS specific manner (Haas et al., 2003). Further, embry-
onic cells may repress other retroviruses through their dis-
tinct PBS sequences (Yamauchi et al., 1995).
The existence of a natural mechanism for the silencing
of MLV proviruses may serve as a model for the engineer-
ing of similar silencing of human viruses of clinical impor-
tance (Ellis, 2005). Thus, it may prove possible to activate
the silencing machinery in more mature cells that would
otherwise be susceptible to infection. In addition, several
groups have used artificially engineered KRAB domain-
containing transcription factors (which recruit TRIM28 to
silence transcription) to induce silencing of integrated
HIV proviruses (Eberhardy et al., 2006; Pengue et al.,
1995). Consistent with our proposed model, one of these
studies showed that an engineered KRAB box transcrip-
tion factor is able to mediate transcriptional silencing of
an integrated HIV-1 provirus when it is targeted to the
PBS of HIV-1 (Eberhardy et al., 2006).
EXPERIMENTAL PROCEDURES
Cell Culture and Stable RNAi-Expressing Cell Line
Production and Transduction
F9 cells were cultured in DMEM with 10% FBS; RAT2 and 293T cells
were cultured in DMEM with 10% FetalcloneII (Hyclone). All cells
were cultured at 37C in 5% CO2. RNAi knockdown was performed
as described before (Leung et al., 2006). For primers used and more
detailed description see the Supplemental Data. For viral transduction
assays, viruses were prepared as for RNAi knockdown using either LJ-
PAdMLPEnh or LJB2-ADMLPEnh vectors (Modin et al., 2000b).
Retroviral preparations were then serially diluted (for titer determina-
tion) and added to F9 and RAT2 cells (seeded at [F9] 3.5 3 103 and
[RAT2] 23 103 cells per cm2 the day prior to transduction) in the pres-
ence of 8 mg of Polybrene/ml. G418-containing selective media was
added 48 hr posttransduction at 1 mg/ml for RAT2 and at 0.5 mg/ml
for F9 and PCC4 cells (for PCC4 cells, media was changed to 1 mg/
ml after 10 days), and colonies were counted after 14–18 days of selec-
tion. Each experiment was performed in triplicate.
Preparation of Nuclear Extracts
Nuclear extracts were prepared from F9 cells essentially as described
in Yamauchi et al. (1995). See the Supplemental Data for details.Purification of RBS Complex
All procedures were performed at 4C. F9 nuclear extract in buffer C
was dialyzed against Dignam D (20 mM HEPES pH 7.9, 100 mM
KCl, 0.2 mM EDTA) for 24 hr. By gradual addition of powdered ammo-
nium sulfate, samples were raised to 25% saturation. Precipitated pro-
teins were removed by centrifugation and discarded. Extract was then
raised to 40% ammonium sulfate saturation, and after 20 min on ice,
the precipitated material was collected and dissolved in Dignam D
containing 1 M (NH4)2SO4. This extract was applied to a HiTrap butyl
FF column (Amersham) equilibrated with Dignam D containing 1 M
(NH4)2SO4. Proteins were eluted using a linear gradient of decreasing
ammonium sulfate concentration. Fractions collected from column
were concentrated and buffer exchanged into Dignam D using
Amico-Ultra4 100-kDa spin columns (Millipore). Fractions containing
RBS binding activity, as monitored by EMSA, were then applied to
a Sephacryl S-500 gel filtration column equilibrated with Dignam D
(plus 150 mM KCl). Samples were concentrated and monitored for ac-
tivity as before. Positive fractions were used in an EMSA gel and the
shifted DNA band excised.
Chromatin Immunoprecipitations
ChIP protocol was adapted from Fuks et al. (2003). See the Supple-
mental Data for details.
Electrophoretic Mobility Shift Assay
Double-stranded DNA probes were labeled using [g-33P] ATP and a T4
polynucleotide kinase kit (Amersham) and purified with G-25 Sepha-
dex (Roche). DNA sequences of the probes are shown in the Supple-
mental Data. Binding reactions were performed using Modified Thor-
nell binding buffer (Yamauchi et al., 1995) (25 mM HEPES [pH 7.9], 1
mM EDTA, 10% [v/v] glycerol, 5 mM DTT, 25 ng poly(dI-dC) per ml, 5
mM NaCl, 5 mM KCl, 3 mM MgCl2, and 0.1 mM ZnCl2 [no FBS was
added]) (Yamauchi et al., 1995). Probes (50,000 CPM) were incubated
with nuclear extract (prepared in buffer C; 10 ml per reaction) for 25 min
at 30C in a total volume of 20 ml. For supershifts and cold DNA com-
petitions, antibody/cold DNA was added at same time as probe. Bind-
ing reactions were analyzed by electrophoresis on 4% native acrylam-
ide gels (cast in 75mMTris pH 8, 75mMboric acid, 1.5mMEDTA) with
reduced salt running buffer (35 mM Tris pH 8, 35 mM boric acid, 1 mM
EDTA), dried down, and visualized using a phosphorimager screen.
Immunodepletions
Sixty microliters of F9 nuclear extract in 13 Modified Thornell binding
buffer was used per reaction. Three micrograms of each antibody was
added per reaction and incubated at 4C for 2 hr. Twenty microliters of
a slurry of protein A/G sepharose beads was added to each reaction
and incubation was continued a further 2 hr. Reaction mixes were
then spun in a centrifuge at 13K rpm for 1 min, 20 ml of supernatant
was removed, and 50,000 CPM of standard EMSA DNA probe was
added. EMSA was then performed as above.
Protein Identification by Mass Spectrometry
Gel slices were excised and proteins subjected to tryptic digest
followed by peptide identification by lc-ms/ms using a hybrid high-
resolution quadrupole time-of-flight electrospray mass spectrometer.
Results were analyzed using MASCOT database search tool (Matrix
Science).
Adenoviral Production/Infections
Adenoviral production and infections were performed as described in
Ng et al. (2000), except infections were performed in 10%FBS.
Supplemental Data
The Supplemental Data include six supplemental figures and Supple-
mental Experimental Procedures and can be found with this article
online at http://www.cell.com/cgi/content/full/131/1/46/DC1/.Cell 131, 46–57, October 5, 2007 ª2007 Elsevier Inc. 55
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